Business Context and Reporting Period
Senti Biosciences, Inc. (Senti) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies. The company focuses on engineering "smarter medicines" to treat incurable diseases, primarily cancer. The reporting period covers the fiscal year ended December 31, 2024. Senti is classified as a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $0 | $2.6 million |
| Net Loss | $(52.8) million | $(71.1) million |
| Operating Expenses | $61.0 million | $95.3 million |
| Research & Development (R&D) | $34.4 million | $32.2 million |
| General & Administrative (G&A) | $26.4 million | $37.2 million |
| Cash and Cash Equivalents (Year-End) | $48.3 million | $35.9 million |
| Accumulated Deficit | $(297.1) million | $(244.3) million |
| Net Cash Used in Operating Activities | $(41.4) million | $(52.4) million |
Note: The 2023 results included a $21.9 million gain on disposal of business (discontinued operations) related to the sale of manufacturing assets to GeneFab. The 2024 net loss excludes discontinued operations.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped to zero in 2024 from $2.6 million in 2023. This was due to the completion of the Spark Therapeutics research program and the SBIR grant in 2023, with no new contract revenue recognized in 2024.
- Expense Reduction: Total operating expenses decreased by approximately $34.2 million year-over-year. This was primarily driven by a $25.6 million decrease in impairment of long-lived assets (which was $26.0 million in 2023 due to the GeneFab transaction) and a $10.8 million decrease in G&A expenses (largely due to reduced personnel costs and stock-based compensation following a workforce reduction).
- Capital Raise: In December 2024, Senti completed a private placement (PIPE) raising approximately $47.6 million through the sale of Series A redeemable convertible preferred stock and warrants. This significantly improved liquidity compared to the prior year.
- Grant Income: The company received $4.9 million in payments from the California Institute for Regenerative Medicine (CIRM) in 2024, though this was recorded as a liability rather than revenue due to the option to convert the grant to a loan.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for twelve months following the issuance of the financial statements (March 2025). While the December 2024 capital raise extended the runway, existing cash resources are not sufficient to fund operations beyond the next twelve months without additional financing. The company plans to focus resources on the clinical development of its lead product candidate, SENTI-202, and the partnership for SENTI-301A in China.
Clinical Progress
- SENTI-202: Initial Phase 1 clinical data released in December 2024 showed that two of the first three Acute Myeloid Leukemia (AML) patients treated achieved complete remission and were measurable residual disease (MRD) negative. Additional data is expected at the 2025 AACR Annual Meeting.
- SN301A (SENTI-301A): The partner, Celest Therapeutics, initiated a clinical trial in China in late 2024. However, dose-limiting toxicities were observed in early 2025, and the company is evaluating dosing levels to determine the path forward.
Material Risks and Contingencies
- Going Concern: The company requires substantial additional funding to continue operations. Failure to secure financing could force delays or termination of development programs.
- Internal Controls: Senti identified a material weakness in internal control over financial reporting related to a lack of sufficient resources in the finance and accounting function. While remediation efforts are underway, the weakness was not fully remediated as of December 31, 2024.
- Manufacturing Reliance: The company relies entirely on GeneFab (a related party) for manufacturing. Risks include GeneFab's inability to scale production or quality issues.
- Regulatory and Clinical Risk: As a clinical-stage company with novel technology, there is a high risk of failure in clinical trials or regulatory approval. The observed toxicities in the SN301A trial represent a significant development risk.
Key Facts for Investor Verification
- Liquidity Runway: Verify the company's ability to raise additional capital given the "substantial doubt" going concern qualification and the $48.3 million cash balance as of year-end.
- SENTI-202 Data: Monitor the upcoming release of additional clinical data at the 2025 AACR Annual Meeting to confirm the durability of the initial remission results.
- SN301A Toxicity: Assess the outcome of the evaluation regarding dose-limiting toxicities observed in the China trial and whether the program will proceed, be modified, or be terminated.
- Internal Control Remediation: Track the progress of hiring and implementing controls to remediate the material weakness in financial reporting, which impacts the reliability of future financial statements.
- Related Party Transactions: Review the terms of the ongoing agreements with GeneFab (manufacturing) and the financial implications of the waived note receivable and new advance payments made in connection with the PIPE transaction.